MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/cco.0b013e32833d58f2

Медицинская библиотека · Current opinion in oncology · 2010

Mantle cell lymphoma in relapse: the role of emerging new drugs.

Diefenbach Catherine S M, O'Connor Owen A

СтатьяОбзорПеревод пока не подготовлен

Аннотация

PURPOSE OF REVIEW: Despite current advances in the therapy for newly diagnosed mantle cell lymphoma (MCL), relapsed MCL continues to have a poor prognosis. Advances in our understanding of the molecular pathogenesis of MCL are yielding many promising novel therapies.

RECENT FINDINGS: This article reviews the unique biology of MCL and describes how our understanding of its cell cycle dysregulation, and impaired apoptotic pathways is yielding many potential therapeutic targets including cyclin D1 and the cell cycle regulatory proteins, inhibitors of mammalian target of rapamycin, the proteasome, and proapoptotic family members. Recent preclinical and clinical data with cdk inhibitors, histone deacetylase inhibitors, the proteasome inhibitor bortezomib, mammalian target of rapamycin inhibitors, and other experimental strategies such as immunotherapy and microRNA are discussed.

SUMMARY: Understanding these targeted therapies in the context of the biology of MCL, has the potential to develop novel therapeutic platforms for the treatment of relapsed MCL, and will hopefully change the outcome for patients with this challenging clinical condition.

Для цитирования: Diefenbach Catherine S M, O'Connor Owen A. Mantle cell lymphoma in relapse: the role of emerging new drugs.. Current opinion in oncology. 2010. DOI: 10.1097/cco.0b013e32833d58f2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.